The BCL2L1 gene was observed to be significantly over-expressed in the plasma samples of glioma patients relative to healthy controls, and its fold change was observed to be relatively higher in the plasma samples of patients with high-grade glioma compared to patients with low-grade glioma. This evidence concerns the gene BCL2L1 and glioma.